News stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive on Monday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news articles about the pharmaceutical company an impact score of 45.7979045348363 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

Several research firms have recently commented on VRTX. Vetr upgraded Vertex Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $156.00 price target for the company in a research report on Tuesday, July 18th. Jefferies Group LLC restated a “buy” rating and set a $185.00 price target (up from $155.00) on shares of Vertex Pharmaceuticals in a research report on Wednesday, July 19th. Credit Suisse Group raised their price target on Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 19th. Robert W. Baird raised their price target on Vertex Pharmaceuticals from $115.00 to $136.00 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Finally, UBS AG lowered Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price target for the stock from $135.00 to $174.00 in a research report on Wednesday, July 19th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average target price of $162.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.46% during mid-day trading on Monday, hitting $154.49. The stock had a trading volume of 1,082,040 shares. The company has a 50 day moving average price of $144.45 and a 200 day moving average price of $116.40. The stock has a market cap of $38.95 billion, a P/E ratio of 148.41 and a beta of 1.77. Vertex Pharmaceuticals has a one year low of $71.46 and a one year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.33. The company had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals will post $1.60 EPS for the current year.

In other news, EVP Stuart A. Arbuckle sold 70,969 shares of the stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $128.06, for a total transaction of $9,088,290.14. Following the transaction, the executive vice president now owns 145,061 shares of the company’s stock, valued at $18,576,511.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey M. Leiden sold 147,101 shares of the stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $129.50, for a total transaction of $19,049,579.50. Following the transaction, the chief executive officer now directly owns 312,142 shares in the company, valued at approximately $40,422,389. The disclosure for this sale can be found here. Insiders have sold 751,042 shares of company stock worth $113,078,257 in the last ninety days. Corporate insiders own 1.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-vertex-pharmaceuticals-nasdaqvrtx-share-price/1488212.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.